Cell News and Research

RSS

Phase 2 clinical trial results of IMO-2055 announced

Idera Pharmaceuticals, Inc., today announced the presentation of final data from a clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as monotherapy in patients with Renal Cell Carcinoma (RCC). The data are being presented during the Eighth International Kidney Cancer Symposium being held in Chicago, September 25-26, 2009.

28 Sep 2009

FDA grants accelerated approval for Allos Therapeutics’ FOLOTYN

Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

28 Sep 2009

NSERC awards $5M grant to develop faster detection methods for cancer

A nanomedicine research group led by a University of Toronto chemist has received a $5-million grant from the Natural Sciences and Engineering Research Council of Canada (NSERC), giving them the green light to develop faster ways of detecting leukemia and lung cancer cells.

28 Sep 2009

Lonza Group and Patheon extend exclusivity and due diligence period

The Special Committee of Independent Directors of Patheon Inc. (TSX:PTI) and Lonza Group AG (SIX:LONN) today announced the extension until October 15, 2009 of the exclusivity and due diligence period to allow for continued discussions regarding the previously announced non-binding proposal to acquire all of the outstanding restricted voting shares of the Company at a price of US$3.55 per share as well as other possible strategic transactions.

28 Sep 2009

Pfizer to commence Phase 3 trial of oral c-Met and ALK inhibitor

Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.

26 Sep 2009

Morphotek announces preliminary data from Phase II trial of farletuzumab

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).

26 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

NIH grants $5 million to Pittsburgh researchers

Regenerative medicine researchers at the University of Pittsburgh received two grants totaling more than $5 million from the National Institutes of Health (NIH) to explore new methods for cultivating replacement cells from existing tissues and organs.

26 Sep 2009

G-bor Bal-zsi's innovative research in drug resistance earns select honor

A unique approach to understanding how cells develop resistance to drugs has won a scientist at The University of Texas M. D. Anderson Cancer Center a New Innovator Award from the National Institutes of Health.

26 Sep 2009

Stem Cell Therapy International merges with Histostem

Stem Cell Therapy International, Inc. is proud to announce the execution of the Reorganization and Stock Purchase Agreement ("the Agreement") with Histostem Co., Ltd., a Korean company ("Histostem" and together with SCII, "the parties").

25 Sep 2009

The Australian Institute of Policy and Science awards Dr Jake Baum for malaria research

Research aimed at developing drugs that stop malaria parasites from spreading throughout the body has seen Dr Jake Baum, from the Walter and Eliza Hall Institute, named a Young Tall Poppy by the Australian Institute of Policy and Science.

25 Sep 2009

Folotyn approved for the treatment of Peripheral T-Cell Lymphoma

The U.S. Food and Drug Administration has approved Folotyn (pralatrexate), the first treatment for a form of cancer known as Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma.

25 Sep 2009

Dental plaque increases neutrophil activity in black males

Will neglecting to brush your teeth damage more than just your smile? Can failing to attack dental plaque increase your risk of heart damage?

25 Sep 2009

DOR Biopharma to raise $3.85 million from institutional investors

DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biotechnology company, announced today that it has entered into common stock purchase agreements with institutional investors totaling approximately $3.85 million. DOR's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.

25 Sep 2009

NCI awards Altor Bioscience a $3 MM grant to develop its targeted cancer therapeutic ALT-801

Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its clinical development of ALT-801, a novel tumor-targeted immunotherapeutic designed to improve the efficacy and safety of the FDA-approved anticancer cytokine, interleukin-2 (IL-2).

25 Sep 2009

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

YM BioSciences Inc. a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for its fiscal year end, ended June 30, 2009.

25 Sep 2009

UHP's electronic health record system recognized

Urban Health Plan in the South Bronx is revolutionizing the way patients are identified and tracked at their network of community health centers. From identifying patients through an iris recognition scan to managing their patients' health through a fully electronic system, UHP is able to provide state-of-the-art, quality and comprehensive care to thousands of New York's neediest residents. This week, their efforts were recognized by the Healthcare Information and Management Systems Society who awarded them the 2009 HIMSS Davies Award of Excellence. Urban Health Plan uses eClinicalWorks (ECW) as its electronic health record (EHR) system.

25 Sep 2009

Research to develop small-molecule drug that blocks excess iron absorption

Excess iron in the body, if left unchecked, can form toxic deposits in major organs leading to serious conditions including heart failure, diabetes, liver cirrhosis, arthritis, and even infertility. Iron overload can be a consequence of a genetically mutated gene known as hereditary hemochromatosis, or a consequence of red blood cell transfusions, required as life saving treatments, for patients with diseases such as thalassemia.

25 Sep 2009

Neuroscience professor receives Institutes of Health Director's New Innovator Award

Leon Reijmers, PhD, assistant professor of neuroscience at Tufts University School of Medicine in Boston, is one of 55 recipients of the National Institutes of Health Director's New Innovator Award. Reijmers is investigating the way memories are stored in the brain, specifically focusing on the proteins involved in long-term memory storage.

25 Sep 2009

Current stem cell applications to be discussed at NJIT

Stem cell researcher Treena Livingston Arinzeh will discuss current stem cell applications at NJIT, including the regeneration of bone and cartilage for bone fracture and osteoarthritis treatments, spinal cord repair, and liver regeneration at NJIT's first Research Caf.

25 Sep 2009